Zaiding Pharmaceutical announced that total revenue for the first quarter of 2025 was US$106 million, an increase of 22% over the previous year. Net product revenue was $106 million, up 21% year over year. Operating loss was US$56.3 million, down 20% year on year. Adjusted operating loss was US$37.1 million, down 25% year on year. As of March 31, 2025, cash reserves were US$857 million. The company expects revenue guidance of $560 million to $590 million for the full year of 2025.

Zaiding Pharmaceutical announced that total revenue for the first quarter of 2025 was US$106 million, an increase of 22% over the previous year. Net product revenue was $106 million, up 21% year over year. Operating loss was US$56.3 million, down 20% year on year. Adjusted operating loss was US$37.1 million, down 25% year on year. As of March 31, 2025, cash reserves were US$857 million. The company expects revenue guidance of $560 million to $590 million for the full year of 2025.